Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.69 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689083 | 1.00 | ERN1 (0.69) | ERN1PIM1CYP3A4TSHRTDP1 | |
| SCHEMBL544809 | 0.88 | ERN1 (0.78) | ERN1PIM1CYP3A4TSHRTDP1 | |
| SCHEMBL411126 | 0.83 | ERN1 (0.64) | ERN1 | |
| SCHEMBL29384871 | 0.83 | ERN1 (0.64) | ERN1 | |
| SCHEMBL2120180 | 0.82 | ERN1 (1.00) | ERN1CYP3A4TSHRTDP1 | |
| SCHEMBL29371317 | 0.82 | ERN1 (1.00) | ERN1CYP3A4TSHRTDP1 | |
| SCHEMBL12957472 | 0.78 | ERN1 (0.53) | ERN1TRIM24TRIM33 | |
| SCHEMBL5642991 | 0.78 | ERN1 (0.64) | ERN1TDP1 | |
| SCHEMBL6679053 | 0.78 | ERN1 (0.64) | ERN1PIM1CYP3A4TSHRTDP1 | |
| SCHEMBL29743732 | 0.78 | ERN1 (0.64) | ERN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-117233299-A | Method for detecting halogenated polyphenol in drinking water by solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry | 浙江大学 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023040686-A1 | PYRIDAZINONE COMPOUND, PREPARATION METHOD, HERBICIDE COMPOSITION AND USE THEREOF | 江苏中旗科技股份有限公司 | 2023-03-23 | — | — | WO | disclosed |
| CN-108069929-B | 3-substituted coumarin derivative and application thereof, and GPR35 receptor agonist | 中国科学院大连化学物理研究所 | 2021-06-15 | — | — | CN | disclosed |
| CN-108727176-B | Method for preparing 5-halogen-2, 3-dihydroxy benzaldehyde | 荆楚理工学院 | 2021-05-18 | — | — | CN | disclosed |
| WO-2012106534-A2 | HIV INTEGRASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-09 | — | — | WO | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1644337-B1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | ORE PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20030073684-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2003-04-17 | — | — | US | disclosed |
| US-6545150-B2 | Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling | WARNER-LAMBERT COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6440962-B2 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2002-07-18 | — | — | US | disclosed |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265399-B1 | ALKYLATION; CYCLIZATION | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6252070-B1 | REACTING ARYL BROMIDE WITH BUTYLLITHIUM AND ZINC BROMIDE TO GIVE ARYL ZINC BROMIDE; REACTING WITH CORRESPONDING BENZOTHIAZINE COMPOUND | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-1009743-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012916-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | ERN1 1288/4885PIM1 1227/4885CYP3A4 2670/4885 |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | ERN1 1288/4885PIM1 1227/4885CYP3A4 2670/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | ERN1 4855/4885PIM1 4555/4885CYP3A4 1470/4885 |
| US-20030073684-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | ERN1 1288/4885PIM1 1227/4885CYP3A4 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.